MarketsNotableSingle-sourceDeveloping
5.4
Roche H1 revenue growth impacted by CHF strength; FDA decision on breast cancer drug pending
Börsen-Zeitung·CH · US·3 days ago
MarketsSingle-sourceLow
2.0
Krka Group H1 2026 Financial Results Release
Krka Group has published its unaudited interim financial report for the first half of 2026. The report details the company's performance metrics, providing data for investors to assess the pharmaceutical firm's growth trajectory and operational efficiency.
Score Breakdown
Mosaic Score2.0
Confidence0.9
Significance0.1
Source credibility0.1
Related signals
8 foundMarketsNotableSingle-source
5.2
Roche H1 2026 Revenue Declines to 30.4B CHF Amid Currency Headwinds
SRFLO·CH·3 days ago
MarketsNotableSingle-source
5.2
Munich Re reports record H1 profit of 3.9 billion euros on low major loss activity
Zeit OnlineLO·DE·1 day ago
MarketsSingle-source
2.1
JGL reports 16 percent gross profit growth with 38.3 million euro EBITDA
Poslovni DnevnikLO·HR·2 days ago
MarketsSingle-source
2.1
Vidrala reports 9% profit growth in H1 2026
ExpansiónLO·ES·3 days ago
MarketsSingle-source
2.1
Almirall reports 49.4% net profit growth for H1 2026
ExpansiónLO·ES·1 day ago
MarketsSingle-source
2.1
I Love Lund reports Q2 2026 operating loss of 0.8 million SEK
Dagens IndustriLO·SE·1 day ago
MarketsSingle-source
2.1
Sonda reports tripled H1 earnings and revenue growth of 10.8%
La TerceraLO·CL·2 days ago